Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.64 EUR 0.76% Market Closed
Market Cap: 123m EUR

Intrinsic Value

HPHA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one HPHA stock under the Base Case scenario is 2.84 EUR. Compared to the current market price of 2.64 EUR, Heidelberg Pharma AG is Undervalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HPHA Intrinsic Value
2.84 EUR
Undervaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Heidelberg Pharma AG

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
HPHA
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for HPHA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Heidelberg Pharma AG
XETRA:HPHA
DE
Biotechnology
Market Cap
123m EUR
IPO
Nov 13, 2006
DE
Biotechnology
Market Cap
123m EUR
IPO
Nov 13, 2006
Price
false
EPS
false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HPHA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Heidelberg Pharma AG
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Heidelberg Pharma AG

Current Assets 52.4m
Cash & Short-Term Investments 36.6m
Receivables 3.2m
Other Current Assets 12.7m
Non-Current Assets 13.4m
PP&E 3.5m
Intangibles 8.9m
Other Non-Current Assets 975.2k
Efficiency

Free Cash Flow Analysis
Heidelberg Pharma AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Heidelberg Pharma AG

Revenue
8.5m EUR
Cost of Revenue
-1.7m EUR
Gross Profit
6.8m EUR
Operating Expenses
-27.2m EUR
Operating Income
-20.4m EUR
Other Expenses
1.6m EUR
Net Income
-18.8m EUR
Fundamental Scores

HPHA Profitability Score
Profitability Due Diligence

Heidelberg Pharma AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 3-Year Average ROE
ROE is Increasing
ROIC is Increasing
40/100
Profitability
Score

Heidelberg Pharma AG's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

HPHA Solvency Score
Solvency Due Diligence

Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
44/100
Solvency
Score

Heidelberg Pharma AG's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 12.14 EUR with a low forecast of 12.02 EUR and a high forecast of 12.5 EUR.

Lowest
Price Target
12.02 EUR
355% Upside
Average
Price Target
12.14 EUR
360% Upside
Highest
Price Target
12.5 EUR
373% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Heidelberg Pharma AG
does not pay dividends
Shareholder Yield

Current shareholder yield for HPHA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

HPHA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one HPHA stock?

The intrinsic value of one HPHA stock under the Base Case scenario is 2.84 EUR.

Is HPHA stock undervalued or overvalued?

Compared to the current market price of 2.64 EUR, Heidelberg Pharma AG is Undervalued by 7%.

Back to Top